Tanabe Research Laboratories USA Inc (TRL) revealed on Thursday that it has successfully submitted its first Investigational New Drug (IND) application with the US Food and Drug administration (FDA) to commence a phase I trial of its Antibody Drug Conjugate TR1801-ADC (MT- 8633) in patients with cMet positive solid tumours.
The company stated the PBDs (pyrrolobenzodiazepine dimer) were developed by its collaborative partner MedImmune, the global biologics research and development arm of AstraZeneca (LSE:AZN), via its proprietary Spirogen technology and licensed to TRL.
PBDs (pyrrolobenzodiazepine dimer) are of an order of magnitude more potent than other warheads currently used with other ADCs and in the case of TR1801-ADC are linked to the antibody via a site-specific conjugation site.
cMet, also referred to as the hepatic growth factor receptor (HGFR), is a validated target expressed on a variety of tumor types including colorectal, NSCLC, gastric, esophageal, pancreatic, bile duct and many other cancers, according to the company.
Tanabe Research Laboratories USA Inc (TRL) is a California based research, development and clinical stage company and a subsidiary of Mitsubishi Tanabe Pharmaceutical Corporation.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT